Join
Live feed
·
INSIDERFilingvia Quantisnow
Janux Therapeutics Inc. logo

Director Lichter Jay was granted 2,500 shares, increasing direct ownership by 55% to 7,083 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
JANX· Janux Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JANX (Janux Therapeutics Inc.) and more on Quantisnow.